Actively Recruiting
Effects of Dialyzer Characteristics and Dialysis Mode on Functional Properties of Albumin in Patients With Chronic Hemodialysis Treatment
Led by Universität Duisburg-Essen · Updated on 2024-08-19
50
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the effects of different dialysis parameters on the functional properties of albumin in patients undergoing hemodialysis for end-stage chronic kidney disease. This condition requires hemodialysis to survive but is associated with increased cardiovascular risks due to chronic inflammation and incomplete removal of toxins. The study aims to explore how dialyzer types and dialysis modes can therapeutically improve albumin function and overall treatment quality. Participants will receive treatments involving hemodialysis, hemodiafiltration, high-flux dialyzers, and low-flux dialyzers, each for a period of three months. This proof-of-concept interventional study will assess how these different dialysis approaches affect albumin's ability to bind and detoxify harmful substances. The study focuses on comparing the effects of dialysis mode and dialyzer characteristics over a total duration of nine months. Throughout the study, researchers will measure the level of irreversibly oxidized albumin (HNA-2) and evaluate albumin's binding and detoxification efficiency at the end of nine months. Participants will be monitored regularly during treatment to assess these outcomes. The study is sponsored by Universität Duisburg-Essen and aims to provide insights into improving long-term hemodialysis treatment quality by modifying albumin functions.
CONDITIONS
Brief Title
Functionality of Albumin in the Context of Hemodialysis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- At least 3 months of hemodialysis treatment (3 times per week) with a stable dialysis regimen
You will not qualify if you...
- Age 18 years or younger
- Less than three months of regular hemodialysis treatments or fewer than 3 treatments per week
- Acute or chronic liver disease at Child stage A or higher or meeting Kings College criteria
- Received commercial human albumin infusion in the last three months
- Acute or severe chronic infections
- Active tumor disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 9 months
Participants receive sequential treatment with different hemodialysis modes and dialyzer types, including hemodialysis, hemodiafiltration, high flux dialyzer, and low flux dialyzer.
Three hemodialysis treatments per week
Trial Site Locations
Total: 1 location
1
University Hospital Essen
Essen, Germany, 45147
Actively Recruiting
Research Team
K
Kristina Boss, PD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here